Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

L. Herrera, C. Stanciu-Herrera, C. Morgan, V. Ghetie, E. S. Vitetta

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

Original languageEnglish (US)
Pages (from-to)2380-2387
Number of pages8
JournalLeukemia and Lymphoma
Volume47
Issue number11
DOIs
StatePublished - Nov 1 2006

Keywords

  • Chemotherapy
  • Childhood leukemia
  • Immunotherapy
  • Immunotoxins
  • Monoclonal antibodies
  • Pre-B ALL

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this